This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Antipsychotic Augmentation With L-Dopa

This study has been completed.
Information provided by (Responsible Party):
George Foussias, Centre for Addiction and Mental Health Identifier:
First received: July 5, 2012
Last updated: March 11, 2016
Last verified: March 2016

Dopamine, a chemical in the brain, has been linked to schizophrenia for a number of years. More recently, there is evidence that certain areas affected in schizophrenia (e.g. motivation, cognition) may reflect too little dopamine, whereas symptoms like hallucinations and delusions have been linked to too much dopamine.

This study is designed to evaluate the safety, tolerability, and efficacy of giving L-dopa (Sinemet) to see if it will improve those symptoms related to too little dopamine. L-dopa has been approved for other medical conditions (e.g. Parkinson's disease) and works to increase levels of dopamine.

The investigators are linking this study with neuroimaging (fMRI) which will allows us to link any changes the investigators might find in clinical symptoms with changes in the brain. This information can prove useful in better understanding the mechanisms that account for these symptoms, as well as possible new treatments.

At present , treatments for these other symptoms that seem important in functional measures of outcome (i.e. deficit symptoms, including amotivation; cognitive symptoms) in schizophrenia have not proven particularly effective. It is hoped that L-dopa may provide a treatment that is more effective; going forward, this information would also be useful in drug development and future lines of investigation.

  1. L-dopa will prove effective in improving deficit (also called 'primary negative' e.g. amotivation) and cognitive symptoms in schizophrenia.
  2. It will be well tolerated and not increase risk of psychotic symptoms when administered in conjunction with their regular antipsychotic medications.

Condition Intervention Phase
Schizophrenia Drug: levodopa/carbidopa (generic version of Sinemet) Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Augmentation of Antipsychotics With L-Dopa (Sinemet)

Resource links provided by NLM:

Further study details as provided by George Foussias, Centre for Addiction and Mental Health:

Primary Outcome Measures:
  • SANS - Schedule for the Assessment of Negative Symptoms [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • MATRICS-Consensus Cognitive Battery [ Time Frame: 8 weeks ]
  • BPRS - Brief Psychotic Rating Scale [ Time Frame: 8 weeks ]
  • SAPS - Schedule for the Assessment of Positive Symptoms [ Time Frame: 8 weeks ]
  • NIMH-MATRICS Brief Negative Symptoms Scale [ Time Frame: 8 weeks ]
  • CGI-S - Clinical Global Impression - Severity Scale [ Time Frame: 8 weeks ]
  • QLS - Quality of Life Scale [ Time Frame: 8 weeks ]
  • CDS - Calgary Depression Scale [ Time Frame: 8 weeks ]
  • SAS - Simpson Angus Scale for Extrapyramidal Symptoms [ Time Frame: 8 weeks ]
  • BARS - Barnes Akathisia Rating Scales [ Time Frame: 8 weeks ]
  • AIMS - Abnormal Involuntary Movement Scale [ Time Frame: 8 weeks ]
  • UKU - Udvalg for Kliniske Undersogelses [ Time Frame: 8 weeks ]
    Measures General Side Effects

  • LUNSERS - Liverpool University Neuroleptic Side-Effect Rating Scale [ Time Frame: 8 weeks ]
  • BIS-11 - Barrett Impulsivity Scale [ Time Frame: 8 weeks ]
  • Y-BOCS - Yale-Brown Obsessive Compulsive Scale [ Time Frame: 8 weeks ]
  • DAI - Drug Attitude Inventory [ Time Frame: 8 weeks ]
  • fMRI - Functional Magnetic Resonance Imaging [ Time Frame: 8 weeks ]
    Changes in Regional Brain Activity

  • SWN - Subjective Well-Being on Neuroleptics Scale [ Time Frame: 8 weeks ]

Enrollment: 13
Study Start Date: September 2012
Study Completion Date: January 2016
Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: L-Dopa (Sinemet)
Augmentation of current antipsychotic treatment with oral L-Dopa (levodopa/carbidopa) up to 900mg daily for 8 weeks
Drug: levodopa/carbidopa (generic version of Sinemet)
Oral levodopa 900mg daily as tolerated.
Other Names:
  • Levodopa/carbidopa
  • Sinemet

Detailed Description:
Pharmacological (and non-pharmacological) strategies that may significantly improve the negative and cognitive symptoms of schizophrenia represent a critical unmet therapeutic need. There is wide acceptance of the notion that both negative and cognitive symptoms are best understood as features of hypo- rather than hyperdopaminergic activity. The primary negative and cognitive symptoms appear central to schizophrenia and predate the neurodevelopmental changes that subsequently give rise to the hyperdopaminergic state underlying positive symptoms. In using L-Dopa specifically, we avoid the abuse potential of agents such as the psychostimulants, or perturbations in pharmacological action as a function of dose, as observed with dopamine agonists. Further, more recent neuroimaging studies have provided in vivo evidence in keeping with the underlying rationale. First, imaging studies have demonstrated that L-dopa induces shifts in activity in both cortical and subcortical structures linked to reward, affect and cognition. Along similar lines, L-dopa-induced changes have been associated with improvement in motivation, cognitive tasks, and affect.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • SCID-confirmed (Structured Clinical Interview for DSM-IV Axis I Disorders) diagnosis of schizophrenia
  • ages 18-55

Exclusion Criteria:

  • history of substance abuse or dependence within 3 months; (ii) positive urine drug screen
  • history or evidence of any disorder that might adversely influence cognitive measures (e.g. mental retardation)
  • presence of serious neurological or general medical condition (e.g., Parkinson's disease, cardiac arrhythmia, epilepsy)
  • clinical or laboratory evidence of uncompensated cardiovascular, endocrine, hematologic, hepatic, pulmonary (including bronchial asthma), or renal disease, narrow-angle glaucoma, malignant melanoma
  • pregnancy/nursing or women of child-bearing age not on regular contraceptive therapy (effects of L-dopa unknown)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01636037

Canada, Ontario
Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M5T 1R8
Sponsors and Collaborators
Centre for Addiction and Mental Health
Principal Investigator: Gary Remington, MD PhD FRCPC Centre for Addiction and Mental Health
  More Information

Additional Information:
Responsible Party: George Foussias, Sub-Investigator, Centre for Addiction and Mental Health Identifier: NCT01636037     History of Changes
Other Study ID Numbers: 156/2011
Study First Received: July 5, 2012
Last Updated: March 11, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by George Foussias, Centre for Addiction and Mental Health:
negative symptoms
deficit syndrome

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Antipsychotic Agents
Carbidopa, levodopa drug combination
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Aromatic Amino Acid Decarboxylase Inhibitors
Enzyme Inhibitors
Adjuvants, Immunologic
Immunologic Factors
Dopamine Agonists processed this record on September 25, 2017